Peptide Receptor Radionuclide Therapy (PRRT)

Подписаться 4,1 тыс.

Просмотров 9 тыс.

50% 1

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).
NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.
What do physicians look forward to in the future for PRRT?

Опубликовано:

26 июл 2024

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист

Посмотреть позже

Комментарии : 12

@kenburk4245 Год назад

I'm down to my last infusion in Jan 2023. Really looking forward to my first scan after treatment.

@latasha3472 3 года назад

I completed this treatment last year and it definitely work my tumor definitely shrunk a lot and I have less symptoms now.

@CarcinoidNETs 3 года назад

Thanks so much for sharing the positive effects of your treatment, Latasha.

@pdrey100 2 года назад

What was your original tumor size and what was your SUVmax value from a dotatate scan pre treatment? Thank you.

@loveleighmurf 3 года назад

It does seem to be the first line of treatment for pheochromocytoma/parangaliomas if inoperable (and if they are a candidate for it)

@vamsinadh3159 3 года назад

When alpha emitter is suggested. Is ac-225 is safer than lu-177

@CarcinoidNETs 3 года назад

Hi Vamsi, here's an article that may answer your questions regarding the difference between using alpha emitters versus beta emitters in PRRT, www.sciencedirect.com/science/article/pii/S000129981930100X. This is definitely a question to raise with your own physician/team of physicians.

@umarsalafi8306 3 года назад

how many doses of prrt therapy can you have maximum

@latasha3472 3 года назад

I read 10

@johnrivas2710 3 года назад

Has this treatment been tested on patients with poorly differentiated or high grade neuroendocrine carcinoma? If so what was the result?

@CarcinoidNETs 3 года назад

Hi John, here are some articles that might be of interest regarding PRRT and poorly differentiated neuroendocrine tumors, PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3), erc.bioscientifica.com/view/journals/erc/27/3/ERC-19-0400.xml, and an abstract from a study, Treatment of High Grade Metastatic Neuroendocrine Tumor (mNET) with Peptide Receptor Radionuclide Therapy (PRRT) Retrospective Analysis in a Single Referral Center, nanets.net/abstracts-archive/2015/363-c05-treatment-of-high-grade-metastatic-neuroendocrine-tumor-mnet-with-peptide-receptor-radionuclide-therapy-prrt-retrospective-analysis-in-a-single-referral-center/file. We hope these provide helpful information.

@latasha3472 2 года назад

I have high grade neuroendocrine pancreatic and it worked beautifully my tumor shrunk a lot